The role of helper and regulatory T cells in the pathogenesis of vitiligo

Başak, Pınar Yüksel; Adiloğlu, Ali Kudret; Ceyhan, Ali Murat; Taş, Tekin; Akkaya, Vahide Baysal

doi:10.1016/j.jaad.2008.09.048

Cited by 121 publications

(135 citation statements)

References 14 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…A number of studies indicate that decreased TGFin vitiligo patients, and this could have a deleterious effect upon Treg cell function in these individuals [58][59][60]. In addition, serum concentrations of TGF-have been shown to be decreased in cases of active but not stable vitiligo, indicating that lower levels of the cytokine are positively correlated with disease progression [61].…”

Section: Transforming Growth Factor-mentioning

confidence: 99%

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Dwivedi

Kemp

Laddha

et al. 2015

Autoimmunity Reviews

110

View full text Add to dashboard Cite

Vitiligo is a hypomelanotic autoimmune skin disease arising from a breakdown in immunological self-tolerance, which leads to aberrant immune responses against melanocytes.Regulatory T cells (Tregs) are crucial to the development of self-tolerance and so are major foci in the study of autoimmune pathogenesis of vitiligo. This review will summarise recent findings concerning the role of Tregs in the pathogenesis of vitiligo. In addition, as antigen-specific Tregs are a potential route for the reinstatement of immune tolerance, new strategies that expand or induce de novo generation of Tregs and which are currently being investigated as therapies for other autoimmune diseases, will be discussed. These approaches will highlight the opportunities for Treg cell-based therapeutics in vitiligo.4

show abstract

Section: Transforming Growth Factor-mentioning

confidence: 99%

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Dwivedi

Kemp

Laddha

et al. 2015

Autoimmunity Reviews

110

View full text Add to dashboard Cite

show abstract

“…Başak ve ark. 'nın yaptığı çalışmada ise serum İL-17 düzeylerinin, hastalığın başlangıç yaşının erken olması ve tutulum olan vücut yüzey alanıyla korele olarak yüksek olduğu görülmüştür 3 . Hastalığın erken yaşlarda başladığı hastalarda İL-17 düzeyinin yüksek olmasını, İL-17'nin farklı bir mekanizmayla hastalığın başlangıç döneminde immünolojik cevaba katkısı olmasına bağlamıştır.…”

Section: Discussionunclassified

“…İlk olarak Başak ve ark. vitiligolu hastaların serumlarında İL-17'yi yüksek olarak bulmuştur 3 . Daha sonra yapılan çalışmalar da vitiligolu hastaların serumlarında İL-17'nin yüksek olduğu görüşünü desteklemiştir 4,5 .…”

Section: Introductionunclassified

Serum IL-23 levels in patients with vitiligo

Cengiz¹,

Emiroğlu²,

Cemil³

et al. 2014

TURKDERM

View full text Add to dashboard Cite

Background and Design: Interleukin-23 (IL-23) is a cytokine which is believed to have an important role in the pathogenesis of autoimmune diseases. Therefore, it can be used as a target molecule in the treatment of autoimmune diseases. The aim of our study was to determine serum IL-23 levels in patients with vitiligo to understand their possible roles in the disease etiology and to compare the results with the healthy controls. Materials and Methods: Fifty-one patients, who applied to the dermatology outpatient clinic and were diagnosed with vitiligo clinically and by wood lamp inspection, were enrolled in our study. Thirty-six age-and sex-matched healthy subjects were also enrolled as the control group. Serum IL-23 levels were studied in peripheral venous blood samples. Statistical analyses were made by SPSS version 16.0 for Windows . Results: Vitiligo group and control group were similar in terms of age and sex. Generalized type vitiligo was detected in 27 (52,9%), whereas focal, acrofacial, segmental and universal forms were detected in 13 (25,5%), 5 (9,8%), 3 (5,9%) and 3 (5,9%) of the patients, respectively. Mean serum IL-23 values were not significantly different between patient and control group (p=0.606). We also showed that serum IL-23 levels

show abstract

“…Por su parte, la expresión del factor estimulante de colonias de monocitos y granulocitos, de las células madres y el factor básico de crecimiento fibroblástico (cuya función es estimular a las células con pigmentos) es menor en la piel con vitiligo que en la piel perilesional, en la no lesionada así como en la de los controles sanos 18 . a su vez, se han encontrado una disminución en los niveles séricos del factor de crecimiento transformante beta en pacientes con vitiligo 19 , lo cual puede aumentar la respuesta de los LT cD8+ y disminuir la maduración de las células T reguladoras, causando deterioro en la inhibición de la inflamación en el vitiligo. La modulación en la producción de citoquinas por monocitos, macrófagos y LT cD4, así como de antagonistas de citoquinas, corresponde al mecanismo anti-inflamatorio más importante de la IGIV, permitiendo que el perfil clásico de citoquinas regrese a la normalidad 4,11,13 .…”

Section: Discussionunclassified

Vitiligo y terapia con inmunoglobulina intravenosa: a propósito de un paciente con síndrome de Sjögren

2011

Rev. méd. Chile

View full text Add to dashboard Cite

Remission of vitiligo during treatment with intravenous immunoglobulin. Report of one caseVitiligo is associated with other autoimmune diseases. We report a 52-year-old male with a Sjögren syndrome that was treated with monthly pulses of intravenous immunoglobulin for a chronic inflammatory demyelinating polyradiculoneuropathy. The neurological disorder responded adequately to the treatment and the patient also noted a marked remission of his vitiligo with almost compete re-pigmentation of the scalp and face and partial re-pigmentation of other areas. (Rev Med Chile 2011; 139: 484-488 E l vitiligo es un trastorno de la pigmentación cutánea, caracterizado por la presencia de áreas de piel despigmentada, secundario a la pérdida crónica y progresiva de los melanocitos epidérmicos. a nivel mundial tendría una prevalencia entre 0,5-2% según las diferentes series, aunque en estudios recientes se ha sugerido que esta cifra podría estar sobrestimada 1 .Su etiología es aún incierta, sin embargo, ha sido establecido que en pacientes genéticamente susceptibles, factores como la autoinmunidad, las infecciones, el estrés, anormalidades neurológicas, disfunciones en el receptor de la melatonina, de la migración del melanocito y de origen tóxico, entre otros, podrían tener un rol patogénico 2 .En relación al proceso autoinmune, existiría participación directa del sistema inmunológico, tanto de la rama humoral como celular. La primera se caracteriza por presencia de anticuerpos contra múltiples antígenos expresados en los melanocitos y la segunda por el reclutamiento de linfocitos T (LT) cD8+ citotóxicos y macrófagos. Posiblemente, la destrucción inicial de los melanocitos sería consecuencia de la acumulación de metabolitos tóxicos y posterior amplificación autoinmune del daño sobre éstos.clínicamente puede manifestarse en forma segmentaria o difusa, asociándose esta última variedad a diversas enfermedades autoinmunes, entre las que destacan la tiroiditis de Hashimoto, el lupus eritematoso sistémico y la anemia perniciosa. Estas etiologías autoinmunes representan 30% del total de pacientes con la forma difusa 2 .Desde el punto de vista psicosocial, el vitiligo puede tener un alto impacto en la autoestima y calidad de vida del paciente afectado, incluso mayor al asociado con la psoriasis. actualmente, disponemos de diversas aproximaciones terapéuticas para esta patología, las que dependen principalmente de la extensión del compromiso cutáneo y del tipo de piel, sin embargo, no existe hasta el momento un tratamiento completamente efectivo 3 .La terapia con inmunoglobulina intravenosa (IGIV) posee un complejo mecanismo de acción. Someramente podemos resumir sus funciones en: modulación de la expresión y función de los receptores Fc, interferencia con la activación del complemento y la red de citoquinas, provisión de anticuerpos anti-idiotipo, modulación de las células dendríticas e interferencia con la activación y función de los linfocitos b y T, siendo esta última,

show abstract

The role of helper and regulatory T cells in the pathogenesis of vitiligo

Cited by 121 publications

References 14 publications

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Serum IL-23 levels in patients with vitiligo

Vitiligo y terapia con inmunoglobulina intravenosa: a propósito de un paciente con síndrome de Sjögren

Contact Info

Product

Resources

About